Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, settembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Twist Bioscience Corp
TWST
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$155.56
12.49
8.73%
In chiusura: Sep 16, 5:00 PM EST
$157.35
14.28
9.98%
Pre-mercato: 5:46 AM EST
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Twist Bioscience Financials
Twist Bioscience (TWST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Twist Bioscience Q3 EPS $(0.56) Misses $(0.50) Estimate, Sales $118.376M Beat $114.490M Estimate
Benzinga Newsdesk
PRO
Twist Bioscience Raises FY2026 Sales Guidance from $442.000M-$447.000M to $456.000M-$457.000M vs $446.103M Est
Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to $456.000 million-$457.000 million vs $446.103 million estimate.
Benzinga Newsdesk
PRO
Twist Bioscience Sees Q4 Sales $123.000M-$124.000M vs $117.546M Est
Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 million analyst estimate.
Benzinga Newsdesk
These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results
Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability and raised FY sales guidance. Analysts raise price targets.
Avi Kapoor
AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens
Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene portfolio.
Vandana Singh
PRO
Twist Bioscience Q2 Adj. EPS $(0.59) Misses $(0.48) Estimate, Sales $110.715M Beat $107.657M Estimate
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.48) by 22.92 percent. This is a 10.61 percent increase over losses of $(0.66) per share
Benzinga Newsdesk
Privacy Manager